Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wave Life Sci Ord Sh (NQ: WVE )

4.690 -0.050 (-1.05%)
Streaming Delayed Price Updated: 3:26 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Wave Life Sci Ord Sh

< Previous 1 2 Next >
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at Upcoming Investor Conferences
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. 
Via MarketBeat
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.